# Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

> **NCT00162253** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 120 (—)

## Conditions studied

- Psoriasis, Moderate to Severe

## Interventions

- **DRUG:** BMS 587101

## Key facts

- **NCT ID:** NCT00162253
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 120 (—)
- **Last updated:** 2010-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162253, "Study of BMS-587101 in Patients With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00162253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*